Assessment of clarithromycin susceptibility in strains belonging to the Mycobacterium abscessus group by erm(41) and rrl sequencing

Antimicrobial Agents and Chemotherapy

Volumn 55, Issue 2, 2011, Pages 775-781

  Bastian, Sylvaine ^a,b   Veziris, Nicolas ^a,b,c   Roux, Anne Laure ^d,e   Brossier, Florence ^a,b,e   Gaillard, Jean Louis ^c,d   Jarlier, Vincent ^a,b,e   Cambau, Emmanuelle ^a,f,g  

^a Ctr Natl de Reference des Mycobacteries et de la Resistance des Mycobacteries Aux Antituberculeux   (France)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^c SORBONNE UNIVERSITÉ   (France)

^d LABORATOIRE DES SCIENCES DU CLIMAT ET DE L ENVIRONNEMENT   (France)

^e HÔPITAL AMBROISE PARÉ   (France)

^f UNIVERSITÉ PARIS DESCARTES   (France)

^g SAINT LOUIS HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AZITHROMYCIN; CLARITHROMYCIN; RNA 23S;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL GENE; BACTERIAL STRAIN; BACTERIUM ISOLATE; BRONCHIECTASIS; BROTH DILUTION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CODON; CYSTIC FIBROSIS; EPSILOMETER TEST; GENE DELETION; GENE MUTATION; GENE SEQUENCE; GENOTYPE; HUMAN; IMMUNE DEFICIENCY; INCUBATION TIME; LUNG CANCER; MINIMUM INHIBITORY CONCENTRATION; MYCOBACTERIUM; MYCOBACTERIUM ABSCESSUS; MYCOBACTERIUM BOLLETII; MYCOBACTERIUM MASSILIENSE; NONHUMAN; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; TUBERCULOSIS;

ANTI-BACTERIAL AGENTS; AZITHROMYCIN; CLARITHROMYCIN; DNA, BACTERIAL; GENES, RRNA; HUMANS; METHYLTRANSFERASES; MICROBIAL SENSITIVITY TESTS; MOLECULAR SEQUENCE DATA; MYCOBACTERIUM; MYCOBACTERIUM INFECTIONS; RNA, RIBOSOMAL, 23S; SEQUENCE ANALYSIS, DNA;

EID: 78751689394     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00861-10     Document Type: Article

References (49)

1. Adekambi, T., P. Berger, D. Raoult, and M. Drancourt. 2006. rpoB gene sequence-based characterization of emerging non-tuberculous mycobacteria with descriptions of Mycobacterium bolletii sp. nov., Mycobacterium phocaicum sp. nov. and Mycobacterium aubagnense sp. nov. Int. J. Syst. Evol. Microbiol. 56:133-143.
2. Adekambi, T., and M. Drancourt. 2009. Mycobacterium bolletii respiratory infections. Emerg. Infect. Dis. 15:302-305.
3. Adekambi, T., et al. 2004. Amoebal coculture of "Mycobacterium massiliense" sp. nov. from the sputum of a patient with hemoptoic pneumonia. J. Clin. Microbiol. 42:5493-5501.
4. Aubry, A., V. Jarlier, S. Escolano, C. Truffot-Pernot, and E. Cambau. 2000. Antibiotic susceptibility pattern of Mycobacterium marinum. Antimicrob. Agents Chemother. 44:3133-3136.
5. Ballarino, G. J., K. N. Olivier, R. J. Claypool, S. M. Holland, and D. R. Prevots. 2009. Pulmonary nontuberculous mycobacterial infections: antibiotic treatment and associated costs. Respir. Med. 103:1448-1455.
6. Bosne-David, S., V. Barros, S. C. Verde, C. Portugal, and H. L. David. 2000. Intrinsic resistance of Mycobacterium tuberculosis to clarithromycin is effectively reversed by subinhibitory concentrations of cell wall inhibitors. J. Antimicrob. Chemother. 46:391-395.
7. Brossier, F., N. Veziris, C. Truffot-Pernot, V. Jarlier, and W. Sougakoff. 2006. Performance of the genotype MTBDR line probe assay for detection of resistance to rifampin and isoniazid in strains of Mycobacterium tuberculosis with low- and high-level resistance. J. Clin. Microbiol. 44:3659-3664.
8. Brown-Elliott, B. A., and R. J. Wallace, Jr. 2002. Clinical and taxonomic status of pathogenic nonpigmented or late-pigmenting rapidly growing mycobacteria. Clin. Microbiol. Rev. 15:716-746.
9. Buriankova, K., et al. 2004. Molecular basis of intrinsic macrolide resistance in the Mycobacterium tuberculosis complex. Antimicrob. Agents Chemother. 48:143-150.
10. Cambau, E., et al. 2009. Evaluation of a new test, Genotype HelicoDR, for molecular detection of antibiotic resistance in Helicobacter pylori. J. Clin. Microbiol. 47:3600-3607.
11. Cremades, R., et al. 2009. Mycobacterium abscessus from respiratory isolates: activities of drug combinations. J. Infect. Chemother. 15:46-48.
12. Dauendorffer, J. N., et al. 2003. Identification of mycobacterial species by PCR sequencing of quinolone resistance-determining regions of DNA gyrase genes. J. Clin. Microbiol. 41:1311-1315.
13. Devallois, A., K. S. Goh, and N. Rastogi. 1997. Rapid identification of mycobacteria to species level by PCR-restriction fragment length polymorphism analysis of the hsp65 gene and proposition of an algorithm to differentiate 34 mycobacterial species. J. Clin. Microbiol. 35:2969-2973.
14. Esther, C. R., Jr., D. A. Esserman, P. Gilligan, A. Kerr, and P. G. Noone. 2010. Chronic Mycobacterium abscessus infection and lung function decline in cystic fibrosis. J. Cyst. Fibros. 9:117-123.
15. Griffith, D. E., et al. 2007. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am. J. Respir. Crit. Care Med. 175:367-416.
16. Griffith, D. E., W. M. Girard, and R. J. Wallace, Jr. 1993. Clinical features of pulmonary disease caused by rapidly growing mycobacteria. An analysis of 154 patients. Am. Rev. Respir. Dis. 147:1271-1278.
17. Jeon, K., et al. 2009. Antibiotic treatment of Mycobacterium abscessus lung disease: a retrospective analysis of 65 patients. Am. J. Respir. Crit. Care Med. 180:896-902.
18. Kim, B. J., et al. 1999. Identification of mycobacterial species by comparative sequence analysis of the RNA polymerase gene (rpoB). J. Clin. Microbiol. 37:1714-1720.
19. Kim, H. Y., et al. 2010. Mycobacterium massiliense is differentiated from Mycobacterium abscessus and Mycobacterium bolletii by erythromycin ribosome methyltransferase gene (erm) and clarithromycin susceptibility patterns. Microbiol. Immunol. 54:347-353.
20. Kim, H. Y., et al. 2008. Proportions of Mycobacterium massiliense and Mycobacterium bolletii strains among Korean Mycobacterium chelonae-Mycobacterium abscessus group isolates. J. Clin. Microbiol. 46:3384-3390.
21. Kirschner, P., et al. 1993. Genotypic identification of mycobacteria by nucleic acid sequence determination: report of a 2-year experience in a clinical laboratory. J. Clin. Microbiol. 31:2882-2889.
22. Koh, S. J., et al. 2010. An outbreak of skin and soft tissue infection caused by Mycobacterium abscessus following acupuncture. Clin. Microbiol. Infect. 16:895-901.
23. Kusunoki, S., and T. Ezaki. 1992. Proposal of Mycobacterium peregrinum sp. nov., nom. rev., and elevation of Mycobacterium chelonae subsp. abscessus (Kubica et al.) to species status: Mycobacterium abscessus comb. nov. Int. J. Syst. Bacteriol. 42:240-245.
24. Leao, S. C., et al. 2009. Characterization of mycobacteria from a major Brazilian outbreak suggests that revision of the taxonomic status of members of the Mycobacterium chelonae-M. abscessus group is needed. J. Clin. Microbiol. 47:2691-2698.
25. Levy-Frebault, V., F. Grimont, P. Grimont, and H. David. 1986. Deoxyribonucleic acid relatedness study of the Mycobacterium fortuitum-Mycobacterium chelonae complex. Int. J. Syst. Bacteriol. 36:458-460.
26. Lewis, J. S., II, and J. H. Jorgensen. 2005. Inducible clindamycin resistance in Staphylococci: should clinicians and microbiologists be concerned? Clin. Infect. Dis. 40:280-285.
27. Macheras, E., et al. 2009. Inaccuracy of single-target sequencing for discriminating species of the Mycobacterium abscessus group. J. Clin. Microbiol. 47:2596-2600.
28. Madsen, C. T., et al. 2005. Methyltransferase Erm(37) slips on rRNA to confer atypical resistance in Mycobacterium tuberculosis. J. Biol. Chem. 280: 38942-38947.
29. Maravic, G., M. Feder, S. Pongor, M. Flogel, and J. M. Bujnicki. 2003. Mutational analysis defines the roles of conserved amino acid residues in the predicted catalytic pocket of the rRNA:m6A methyltransferase ErmC′. J. Mol. Biol. 332:99-109.
30. Maxson, S., G. Schutze, and R. Jacobs. 1994. Mycobacterium abscessus osteomyelitis: treatment with clarithromycin. Infect. Dis. Clin. Prac. 3:203-206.
31. Meier, A., et al. 1994. Identification of mutations in 23S rRNA gene of clarithromycin-resistant Mycobacterium intracellulare. Antimicrob. Agents Chemother. 38:381-384.
32. Mushatt, D. M., and R. S. Witzig. 1995. Successful treatment of Mycobacterium abscessus infections with multidrug regimens containing clarithromycin. Clin. Infect. Dis. 20:1441-1442.
33. Nash, K. A., B. A. Brown-Elliott, and R. J. Wallace, Jr. 2009. A novel gene, erm(41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae. Antimicrob. Agents Chemother. 53:1367-1376.
34. Nash, K. A., Y. Zhang, B. A. Brown-Elliott, and R. J. Wallace, Jr. 2005. Molecular basis of intrinsic macrolide resistance in clinical isolates of Mycobacterium fortuitum. J. Antimicrob. Chemother. 55:170-177.
35. National Committee for Clinical Laboratory Standards. 2003. Susceptibility testing of mycobacteria, nocardiae, and other aerobic actinomycetes. Approved standard M-24A. National Committee for Clinical Laboratory Standards, Wayne, PA.
36. Park, S., et al. 2008. In vitro antimicrobial susceptibility of Mycobacterium abscessus in Korea. J. Korean Med. Sci. 23:49-52.
37. Radhakrishnan, D. K., et al. 2009. Non-tuberculous mycobacteria in children with cystic fibrosis: isolation, prevalence, and predictors. Pediatr. Pulmonol. 44:1100-1106.
38. Ripoll, F., et al. 2009. Non mycobacterial virulence genes in the genome of the emerging pathogen Mycobacterium abscessus. PLoS One 4:e5660.
39. Roux, A. L., et al. 2009. Multicenter study of prevalence of nontuberculous mycobacteria in patients with cystic fibrosis in France. J. Clin. Microbiol. 47:4124-4128.
40. Sermet-Gaudelus, I., et al. 2003. Mycobacterium abscessus and children with cystic fibrosis. Emerg. Infect. Dis. 9:1587-1591.
41. Stoffels, K., H. Traore, F. Vanderbist, and M. Fauville-Dufaux. 2009. The effect of combined tobramycin-clarithromycin on Mycobacterium tuberculosis isolates. Int. J. Tuber. Lung Dis. 13:1041-1044.
42. van Ingen, J., R. de Zwaan, R. P. Dekhuijzen, M. J. Boeree, and D. van Soolingen. 2009. Clinical relevance of Mycobacterium chelonae-abscessus group isolation in 95 patients. J. Infect. 59:324-331.
43. Viana-Niero, C., et al. 2008. Molecular characterization of Mycobacterium massiliense and Mycobacterium bolletii in isolates collected from outbreaks of infections after laparoscopic surgeries and cosmetic procedures. J. Clin. Microbiol. 46:850-855.
44. Wallace, R. J., Jr., et al. 1996. Genetic basis for clarithromycin resistance among isolates of Mycobacterium chelonae and Mycobacterium abscessus. Antimicrob. Agents Chemother. 40:1676-1681.
45. Wolinsky, E. 1979. Nontuberculous mycobacteria and associated diseases. Am. Rev. Respir. Dis. 119:107-159.
46. Woods, G. L. 2000. Susceptibility testing for mycobacteria. Clin. Infect. Dis. 31:1209-1215.
47. Woods, G. L., et al. 2000. Multisite reproducibility of Etest for susceptibility testing of Mycobacterium abscessus, Mycobacterium chelonae, and Mycobacterium fortuitum. J. Clin. Microbiol. 38:656-661.
48. Woods, G. L., et al. 1999. Multisite reproducibility of results obtained by the broth microdilution method for susceptibility testing of Mycobacterium abscessus, Mycobacterium chelonae, and Mycobacterium fortuitum. J. Clin. Microbiol. 37:1676-1682.
49. Zelazny, A. M., et al. 2009. Cohort study of molecular identification and typing of Mycobacterium abscessus, Mycobacterium massiliense, and Mycobacterium bolletii. J. Clin. Microbiol. 47:1985-1995.